Valiant(SZ:002643) Tianfeng Securities·2025-08-27 01:14Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6][18]. Core Views - The company reported a revenue of 1.87 billion yuan in the first half of 2025, a year-on-year decrease of 4.4%, while the net profit attributable to the parent company was 218 million yuan, an increase of 1.35% year-on-year [1]. - The functional materials segment saw a revenue decline of 9.55% year-on-year, while the life sciences and pharmaceuticals segment experienced a revenue increase of 20.80% year-on-year [2]. - The company has made significant advancements in high-end new materials, with multiple products in the OLED and polymer sectors already validated by downstream customers [3]. Financial Performance - The company adjusted its net profit forecast for 2025-2027 to 520 million, 631 million, and 704 million yuan respectively, maintaining the "Buy" rating [4]. - The financial data indicates a projected revenue of 3.82 billion yuan for 2025, with a growth rate of 3.55% [5]. - The earnings per share (EPS) is expected to be 0.56 yuan in 2025, with a price-to-earnings (P/E) ratio of 24.56 [5]. Segment Analysis - The functional materials segment contributed 78.58% to total revenue, while the life sciences segment accounted for 20.09% [2]. - The subsidiary MP Biomedicals reported a revenue increase of 33.1% year-on-year, indicating strong demand for its products [2]. - The company is actively developing new materials for various applications, including thermoplastic polyimide and solid-state battery materials, which are currently in the laboratory development stage [3].